

# Pedro Jares

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6415828/publications.pdf>

Version: 2024-02-01

108  
papers

10,673  
citations

61977  
43  
h-index

40976  
93  
g-index

110  
all docs

110  
docs citations

110  
times ranked

12397  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. <i>EBioMedicine</i> , 2022, 75, 103801.	6.1	47
2	Comparison of the Idylla <sup>®</sup> MSI assay with the Promega <sup>®</sup> MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1031-1039.	2.8	6
3	Pathogenesis of Penile Squamous Cell Carcinoma: Molecular Update and Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 251.	4.1	10
4	An Immune-metabolic signature (IMMETCOLS) identifies three clusters in mCRC with different immune-phenotype distribution and potential clinical implications.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15534-e15534.	1.6	0
5	14-gene immunoglobulin (IGG) and proliferation signatures and association with overall survival across cancer-types.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2636-2636.	1.6	6
6	A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 213-225.	7.0	10
7	IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. <i>Blood</i> , 2021, 137, 2935-2946.	1.4	49
8	Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice. <i>Journal of Thoracic Disease</i> , 2021, 13, 1658-1670.	1.4	4
9	EBUS-TBNA Cytological Samples for Comprehensive Molecular Testing in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2084.	3.7	21
10	Submucosal gland adenocarcinoma of the esophagus. A rare non-Barrett's associated tumor. <i>Gastroenterology &amp; Hepatology</i> , 2021, 44, 367-369.	0.5	0
11	Molecular Landscape of Vulvar Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7069.	4.1	14
12	Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions. <i>Diagnostics</i> , 2021, 11, 1319.	2.6	3
13	Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 710596.	2.8	5
14	Molecular Pathogenesis of Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 795-807.	2.2	40
15	TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas. <i>Annals of Translational Medicine</i> , 2020, 8, 1218-1218.	1.7	7
16	The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome. <i>Nature Cancer</i> , 2020, 1, 1066-1081.	13.2	51
17	Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients. <i>Diagnostics</i> , 2020, 10, 902.	2.6	1
18	Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. <i>Blood</i> , 2020, 136, 1419-1432.	1.4	131

#	ARTICLE	IF	CITATIONS
19	The IGLV3-21R110 Defines a Subset of Chronic Lymphocytic Leukemia with Intermediate Epigenetic Subtype and Poor Outcome. <i>Blood</i> , 2020, 136, 43-44.	1.4	1
20	Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. <i>Cancers</i> , 2020, 12, 1124.	3.7	5
21	Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients. , 2020, 1, 101-108.		4
22	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 303.	2.8	8
23	Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report. <i>Clinical Lung Cancer</i> , 2019, 20, e219-e223.	2.6	15
24	Differential expression of long non-coding <sc>RNA</sc>s are related to proliferation and histological diversity in follicular lymphomas. <i>British Journal of Haematology</i> , 2019, 184, 373-383.	2.5	12
25	Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. <i>Blood</i> , 2018, 131, 2283-2296.	1.4	106
26	The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2318-2326.	1.3	5
27	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , 2018, 132, 413-422.	1.4	89
28	Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms. <i>Journal of Clinical Investigation</i> , 2018, 128, 4132-4147.	8.2	31
29	Phase II trial of afatinib in patients with advanced/metastatic urothelial carcinoma (UC) with genetic alterations in ERBB receptors 1-3 who failed on platinum-based chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS540-TPS540.	1.6	3
30	Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. <i>Haematologica</i> , 2017, 102, e360-e363.	3.5	27
31	Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 1777-1786.	6.4	58
32	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. <i>Journal of Clinical Oncology</i> , 2017, 35, 1668-1677.	1.6	102
33	Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 127, 2122-2130.	1.4	260
34	Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. <i>Cancer Cell</i> , 2016, 30, 806-821.	16.8	103
35	Clinical Impact of the Quantitative Subclonal Architecture in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 2024-2024.	1.4	0
36	p16INK4a overexpression is associated with CDKN2A mutation and worse prognosis in HPV-negative laryngeal squamous cell carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 375-382.	2.8	33

#	ARTICLE	IF	CITATIONS
37	Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2015, 526, 519-524.	27.8	749
38	Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. <i>Genome Research</i> , 2014, 24, 212-226.	5.5	175
39	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. <i>Blood</i> , 2014, 123, 3790-3796.	1.4	97
40	RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. <i>European Journal of Cancer</i> , 2014, 50, 1973-1981.	2.8	31
41	SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. <i>Blood</i> , 2014, 124, 2235-2247.	1.4	94
42	Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases. <i>Blood</i> , 2014, 124, 1677-1677.	1.4	4
43	Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome. <i>Clinical and Translational Oncology</i> , 2013, 15, 3-8.	2.4	41
44	Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop. <i>Leukemia and Lymphoma</i> , 2013, 54, 1882-1890.	1.3	9
45	Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. <i>International Journal of Cancer</i> , 2013, 133, 2852-2863.	5.1	15
46	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 18250-18255.	7.1	488
47	SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. <i>Blood</i> , 2013, 121, 2175-2185.	1.4	129
48	Molecular Subsets of Mantle Cell Lymphoma Defined by the <i>IGHV</i> Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features. <i>Cancer Research</i> , 2012, 72, 5307-5316.	0.9	231
49	Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA—a simultaneous study of 130 potentially functional SNPs in 14 candidate genes. <i>Rheumatology</i> , 2012, 51, 841-851.	1.9	38
50	Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2012, 44, 1236-1242.	21.4	525
51	Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2012, 44, 47-52.	21.4	893
52	Molecular pathogenesis of mantle cell lymphoma. <i>Journal of Clinical Investigation</i> , 2012, 122, 3416-3423.	8.2	325
53	Incidence and patterns of phospho insulin growth factor receptor-1 (pIGF-1R) and matrilysin (MMP7) expression in metastatic colorectal cancer (mCRC), and correlation with KRAS status: A prospective evaluation in the PULSE trial—A GEMCAD study.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14041-e14041.	1.6	0
54	Influence of BRAF mutations and RAC1b/RAC1 mRNA expression ratio on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3553-3553.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature, 2011, 475, 101-105.	27.8	1,364
56	The Expression of the Endoplasmic Reticulum Stress Sensor BiP/GRP78 Predicts Response to Chemotherapy and Determines the Efficacy of Proteasome Inhibitors in Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2011, 179, 2601-2610.	3.8	57
57	Molecular Pathogenesis of Mantle Cell Lymphoma: New Perspectives and Challenges With Clinical Implications. Seminars in Hematology, 2011, 48, 155-165.	3.4	16
58	Identification of Methylated Genes Associated with Aggressive Clinicopathological Features in Mantle Cell Lymphoma. PLoS ONE, 2011, 6, e19736.	2.5	32
59	Epigenetic Activation of SOX11 in Lymphoid Neoplasms by Histone Modifications. PLoS ONE, 2011, 6, e21382.	2.5	38
60	Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood, 2011, 117, 4836-4843.	1.4	280
61	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica, 2011, 96, 996-1001.	3.5	100
62	Mantle Cell Lymphoma. , 2011, , 333-348.		8
63	Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood, 2010, 116, 953-961.	1.4	122
64	Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology, 2010, 51, 974-985.	7.3	141
65	Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. Cancer Research, 2010, 70, 1408-1418.	0.9	429
66	Applicability of Different Immunohistochemistry Algorithms to Assess Gene Expression Profile In Patients with Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 4134-4134.	1.4	0
67	MicroRNA Expression, Chromosomal Alterations, and Immunoglobulin Variable Heavy Chain Hypermutations in Mantle Cell Lymphomas. Cancer Research, 2009, 69, 7071-7078.	0.9	78
68	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica, 2009, 94, 1555-1562.	3.5	345
69	Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood, 2009, 113, 3059-3069.	1.4	162
70	The Expression of the ER Stress Sensor GRP78/Bip Is a Target of R-CHOP and Bortezomib Treatments in DLBCL with Prognostic Value. A Rationale for the Use of Proteasome Inhibitors in DLBCL Patients.. Blood, 2009, 114, 3734-3734.	1.4	0
71	Chronic Lymphocytic Leukemia Apoptotic Cell Death Induced by Glucocorticoids Is Mediated by BIM and GILZ and Can Be Predicted by FKBP5 Basal Expression Levels.. Blood, 2009, 114, 1236-1236.	1.4	6
72	Advances in the understanding of mantle cell lymphoma. British Journal of Haematology, 2008, 142, 149-165.	2.5	154

#	ARTICLE	IF	CITATIONS
73	Integrated genomic and expression profiling in mantle cell lymphoma: identification of gene-dosage regulated candidate genes. <i>British Journal of Haematology</i> , 2008, 143, 210-221.	2.5	27
74	Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2008, 68, 10178-10186.	0.9	67
75	Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. <i>Haematologica</i> , 2008, 93, 132-136.	3.5	17
76	Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. <i>Blood</i> , 2007, 109, 5422-5429.	1.4	76
77	Hepatic Expression of Candidate Genes in Patients With Alcoholic Hepatitis: Correlation With Disease Severity. <i>Gastroenterology</i> , 2007, 132, 687-697.	1.3	108
78	Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. <i>Nature Reviews Cancer</i> , 2007, 7, 750-762.	28.4	433
79	Association of CDK4 and CCND1 mRNA overexpression in laryngeal squamous cell carcinomas occurs without CDK4 amplification. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 161-167.	2.8	12
80	SNP Array Analysis Reveals Copy Number Alterations and Uniparental Disomy in Mantle Cell Lymphomas at High Resolution.. <i>Blood</i> , 2007, 110, 1585-1585.	1.4	0
81	Genomic platforms for cancer research: potential diagnostic and prognostic applications in clinical oncology. <i>Clinical and Translational Oncology</i> , 2006, 8, 161-172.	2.4	6
82	Unbalanced expression of licensing DNA replication factors occurs in a subset of mantle cell lymphomas with genomic instability. <i>International Journal of Cancer</i> , 2006, 119, 2768-2774.	5.1	32
83	DNA Microarray Applications in Functional Genomics. <i>Ultrastructural Pathology</i> , 2006, 30, 209-219.	0.9	22
84	Gene Expression Profiling of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p13) and MYST3-CREBBP Rearrangement Reveals a Distinctive Signature with a Specific Pattern of HOX Gene Expression. <i>Cancer Research</i> , 2006, 66, 6947-6954.	0.9	127
85	Gene Expression Profiling of Acute Myeloid Leukemia with Multilineage Dysplasia (AML-MD) Reveals a Biological Diversity Related to Underlying Cytogenetics but Also Identifies a Distinctive Profile in Normal Karyotype AML-MD.. <i>Blood</i> , 2006, 108, 2244-2244.	1.4	64
86	Gene Expression Signature of Acute Myeloid Leukemia (AML) with T(8;16)(P11;P13) and MYST3-CREBBP Rearrangement: A Microarray Study Validated by Multiple Real-Time PCR.. <i>Blood</i> , 2005, 106, 3009-3009.	1.4	0
87	A Xenopus Dbf4 homolog is required for Cdc7 chromatin binding and DNA replication. <i>BMC Molecular Biology</i> , 2004, 5, 5.	3.0	27
88	Gene Expression Profile of Acute Myeloid Leukemia (AML) with t(8;16)(p11;p13) and MYST3/CREBBP Rearrangement.. <i>Blood</i> , 2004, 104, 2054-2054.	1.4	0
89	Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. <i>Haematologica</i> , 2004, 89, 1322-31.	3.5	19
90	Presence of occult cytomegalovirus infection in the brain after orthotopic liver transplantation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 440, 166-171.	2.8	20

#	ARTICLE	IF	CITATIONS
91	Use of Peptides from p21 (Waf1/Cip1) to Investigate PCNA Function in Xenopus Egg Extracts. Experimental Cell Research, 2001, 265, 242-251.	2.6	16
92	The Cdc7/Dbf4 protein kinase: target of the S phase checkpoint?. EMBO Reports, 2000, 1, 319-322.	4.5	80
93	Xenopus Cdc7 function is dependent on licensing but not on XORC, XCdc6, or CDK activity and is required for XCdc45 loading. Genes and Development, 2000, 14, 1528-1540.	5.9	142
94	Disregulation of p16MTS1/CDK4I protein and mRNA expression is associated with gene alterations in squamous-cell carcinoma of the larynx. , 1999, 81, 705-711.		19
95	p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. Journal of Pathology, 1998, 184, 265-271.	4.5	46
96	p16INK4a Gene Inactivation by Deletions, Mutations, and Hypermethylation Is Associated With Transformed and Aggressive Variants of Non-Hodgkin's Lymphomas. Blood, 1998, 91, 2977-2984.	1.4	266
97	Hyperplastic Lesions of the Larynx. Experience of the Barcelona Group. Acta Oto-Laryngologica, 1997, 117, 43-46.	0.9	4
98	Deletions and Loss of Expression of P16INK4a and P21Waf1 Genes Are Associated With Aggressive Variants of Mantle Cell Lymphomas. Blood, 1997, 89, 272-280.	1.4	219
99	p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx. Oncogene, 1997, 15, 1445-1453.	5.9	45
100	CYCLIN D1 AND RETINOBLASTOMA GENE EXPRESSION IN HUMAN BREAST CARCINOMA: CORRELATION WITH TUMOUR PROLIFERATION AND OESTROGEN RECEPTOR STATUS. , 1997, 182, 160-166.		63
101	p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. , 1997, 183, 156-163.		44
102	CYCLIN D1 AND RETINOBLASTOMA GENE EXPRESSION IN HUMAN BREAST CARCINOMA: CORRELATION WITH TUMOUR PROLIFERATION AND OESTROGEN RECEPTOR STATUS. Journal of Pathology, 1997, 182, 160-166.	4.5	3
103	p21WAF1Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. Journal of Pathology, 1997, 183, 156-163.	4.5	1
104	Deletions and Loss of Expression of P16INK4a and P21Waf1 Genes Are Associated With Aggressive Variants of Mantle Cell Lymphomas. Blood, 1997, 89, 272-280.	1.4	9
105	Detection of the bcl-1 Rearrangement at the Major Translocation Cluster in Frozen and Paraffin-Embedded Tissues of Mantle Cell Lymphomas by Polymerase Chain Reaction. American Journal of Clinical Pathology, 1996, 105, 532-537.	0.7	44
106	Increased expression of the PRAD4/CCND1 gene in hairy cell leukaemia. British Journal of Haematology, 1995, 91, 1025-1030.	2.5	97
107	Taq polymorphism of the human tissue inhibitor of metallo-proteinases-2 (Timp2) gene. Human Molecular Genetics, 1994, 3, 218-218.	2.9	0
108	Prognostic significance of the loss of heterozygosity of nm23-h1 and p53 genes in human colorectal carcinomas. Cancer, 1994, 73, 2913-2921.	4.1	65